MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/fcp.12683

Медицинская библиотека · Fundamental & clinical pharmacology · 2021

Chronic use of renin-angiotensin-aldosterone system blockers and mortality in COVID-19: A multicenter prospective cohort and literature review.

Gault Nathalie, Esposito-Farèse Marina, Revest Matthieu, Inamo Jocelyn, Cabié André, Polard Élisabeth, Hulot Jean-Sébastien, Ghosn Jade, Chirouze Catherine, Deconinck Laurène, Diehl Jean-Luc, Poissy Julien, Epaulard Olivier, Lefèvre Benjamin, Piroth Lionel, De Montmollin Etienne, Oziol Eric, Etienne Manuel, Laouénan Cédric, Rossignol Patrick, Costagliola Dominique, Vidal-Petiot Emmanuelle, French-Covid cohort investigators, study group

СтатьяПеревод в очереди

Аннотация

AIMS: The role of renin-angiotensin-aldosterone system (RAAS) blockers on the course of coronavirus disease 2019 (COVID-19) is debated. We assessed the association between chronic use of RAAS blockers and mortality among inpatients with COVID-19 and explored reasons for discrepancies in the literature.

METHODS AND

RESULTS

We included adult hypertensive patients from a prospective nationwide cohort of 3512 inpatients with COVID-19 up to June 30, 2020. Cox proportional hazard models with various adjustment or propensity weighting methods were used to estimate the hazard ratios (HR) of 30-day mortality for chronic users versus non-users of RAAS blockers. We analyzed data of 1160 hypertensive patients: 719 (62%) were male and 777 (67%) were older than 65 years. The main comorbidities were diabetes (n = 416, 36%), chronic cardiac disease (n = 401, 35%), and obesity (n = 340, 29%); 705 (61%) received oxygen therapy. We recorded 135 (11.6%) deaths within 30 days of diagnosis. We found no association between chronic use of RAAS blockers and mortality (unadjusted HR = 1.13, 95% CI [0.8-1.6]; propensity inverse probability treatment weighted HR = 1.09 [0.86-1.39]; propensity standardized mortality ratio weighted HR = 1.08 [0.79-1.47]). Our comprehensive review of previous studies highlighted that significant associations were mostly found in unrestricted populations with inappropriate adjustment, or with biased in-hospital exposure measurement.

CONCLUSION

Our results do not support previous concerns regarding these drugs, nor a potential protective effect as reported in previous poorly designed studies and meta-analyses. RAAS blockers should not be discontinued during the pandemic, while in-hospital management of these drugs will be clarified by randomized trials. NCT04262921.

Для цитирования: Gault Nathalie, Esposito-Farèse Marina, Revest Matthieu, Inamo Jocelyn, Cabié André, Polard Élisabeth, Hulot Jean-Sébastien, Ghosn Jade, Chirouze Catherine, Deconinck Laurène, Diehl Jean-Luc, Poissy Julien, Epaulard Olivier, Lefèvre Benjamin, Piroth Lionel, De Montmollin Etienne, Oziol Eric, Etienne Manuel, Laouénan Cédric, Rossignol Patrick, Costagliola Dominique, Vidal-Petiot Emmanuelle, French-Covid cohort investigators, study group. Chronic use of renin-angiotensin-aldosterone system blockers and mortality in COVID-19: A multicenter prospective cohort and literature review.. Fundamental & clinical pharmacology. 2021. DOI: 10.1111/fcp.12683.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.